CRISPR-Mediated LGMN Gene Editing Reduces Breast Cancer Metastasis: Mechanisms, Methods, and Implications

Study Background and Research Question

Metastasis remains the leading cause of mortality in breast cancer. The lysosomal cysteine endopeptidase legumain (also known as asparagine endopeptidase, AEP), encoded by the LGMN gene, is implicated in promoting invasive and migratory behavior in a range of cancers, including breast, prostate, colorectal, and gastric malignancies. Its overexpression correlates with poor prognosis and enhanced tumor aggressiveness. Given the central role of legumain in lysosomal and autophagic functions, targeting this protease has emerged as a plausible strategy for anti-metastatic therapy. Recent advances in CRISPR/Cas9 genome editing have opened new avenues for precise gene disruption to interrogate and therapeutically target cancer-driving genes. However, achieving efficient and coordinated delivery of both Cas9 mRNA and guide RNAs (gRNAs) remains a technical challenge, especially in translational cancer models.

Key Innovation from the Reference Study

The study by Wang et al. (Scientific Reports, 2024) introduces a co-delivery approach using lipid nanoparticles (LNPs) for simultaneous administration of Cas9 mRNA and gRNAs designed to target the human LGMN gene in breast cancer cells. This dual-delivery system enables efficient CRISPR-mediated disruption of legumain, resulting in marked inhibition of cancer cell migration, invasion, and metastatic colonization. The authors further optimized the in vitro transcription (IVT) protocols for gRNA synthesis, comparing multiple template designs—including linearized plasmids and annealed oligonucleotides driven by the T7 promoter—thereby advancing both the mechanistic understanding and technical toolkit for gene editing in oncology research.

Methods and Experimental Design Insights

To achieve robust knockout of LGMN, the authors designed two types of gRNA templates: (1) a linearized pUC57-T7-gRNA plasmid and (2) T7-gRNA oligonucleotide templates. Both templates incorporated T7 promoter sequences upstream of the gRNA for efficient in vitro transcription using T7 RNA Polymerase, a recombinant enzyme typically expressed in E. coli and renowned for specificity toward the T7 promoter. The gRNA products were subsequently purified and validated for integrity and concentration.

Cas9 mRNA was generated from an optimized plasmid template via IVT and purified to high quality. For functional delivery, the Cas9 mRNA and gRNAs were co-encapsulated in LNPs, a clinically relevant non-viral delivery system. Transfection efficacy, gene editing efficiency, and downstream biological effects were evaluated in breast cancer cell lines using PCR-based genotyping, immunoblotting, migration/invasion assays, and in vivo lung colonization models. Gene editing outcomes were quantitatively assessed by measuring indel frequencies at the LGMN locus and by monitoring changes in lysosomal/autophagic markers.

Protocol Parameters

• gRNA in vitro transcription: Utilize linearized plasmid (e.g., pUC57-T7-gRNA) or annealed T7-gRNA oligo templates with T7 RNA Polymerase; standard reaction conditions at 37°C for 2–4 hours.
• Cas9 mRNA synthesis: Template optimization, capped and polyadenylated in vitro; purification using commercial kits to remove DNA and truncated transcripts.
• LNP formulation: Encapsulate Cas9 mRNA and gRNA in optimized ratios; particle size ~100 nm; test encapsulation efficiency before cell delivery.
• In vitro editing assays: Transfect breast cancer cells with LNPs; assess editing at 36, 48, and 84 hours post-transfection via PCR and sequencing.
• Functional validation: Migration and invasion measured using transwell and wound-healing assays; lysosomal/autophagic markers quantified by immunoblotting.
• In vivo metastasis model: Inject treated cells into mouse tail vein; quantify lung metastases after 3–4 weeks.

Core Findings and Why They Matter

The coordinated delivery of Cas9 mRNA and gRNAs by LNPs led to efficient knockout of LGMN in breast cancer cells, as evidenced by robust indel formation and loss of legumain protein expression (reference). Functional consequences included impaired lysosomal and autophagic degradation, reduced colony formation, and significantly decreased cell migration and invasion in vitro. Notably, in vivo lung metastasis assays demonstrated a marked reduction in metastatic colonization by edited cancer cells, indicating the translational relevance of this approach for suppressing metastatic spread.

Mechanistically, legumain disruption interfered with protease maturation and autophagic flux, highlighting its role in maintaining the tumor microenvironment conducive to metastasis. The study also benchmarked different gRNA IVT template formats, showing that both linearized plasmids and T7-gRNA oligos can generate functional gRNAs, with subtle differences in editing efficiency across time points.

Comparison with Existing Internal Articles

Several internal resources provide context for the technical advances in this study. For instance, "T7 RNA Polymerase: High-Fidelity RNA Synthesis for In Vit..." and "T7 RNA Polymerase: Benchmark DNA-Dependent RNA Polymerase..." detail the utility of T7 RNA Polymerase as a recombinant enzyme expressed in E. coli for high-specificity RNA synthesis from T7 promoter-driven templates. The current study leverages this enzymatic capability for scalable gRNA production, echoing established best practices in in vitro transcription enzyme workflows for RNAi and vaccine research. Moreover, the comparison of linearized plasmid versus oligo-based templates for T7-driven transcription aligns with recent workflow optimizations highlighted in "T7 RNA Polymerase: Precision Engine for In Vitro Transcri...", emphasizing reproducibility and scalability in RNA synthesis for gene editing applications.

Whereas the internal articles focus on the technical robustness and application range of T7 polymerase, Wang et al.'s work extends these principles to a therapeutic context—demonstrating that optimized IVT workflows directly impact the efficacy of CRISPR-based cancer interventions.

Limitations and Transferability

The study is primarily conducted in breast cancer cell lines and murine models, with effects of LGMN disruption measured within these systems. While the data suggest broad potential for targeting legumain in other aggressive tumors, the transferability of the co-delivery strategy and observed phenotypes to diverse cancer types and in clinical settings remains to be established. Potential resistance mechanisms—such as target sequence mutation or compensatory activation of alternative proteases—may also limit long-term therapeutic efficacy. Additionally, the safety and immunogenicity of repeated LNP-mediated CRISPR delivery require further investigation for translational application.

It is important to note that the reported editing efficiencies and phenotypic outcomes may vary depending on template format, RNA quality, and delivery conditions. The authors provide a technical roadmap for optimization, but standardization across laboratories will be needed for widespread adoption.

Research Support Resources

Researchers aiming to reproduce or extend these findings can leverage recombinant T7 RNA Polymerase for the efficient synthesis of gRNAs from T7 promoter-driven templates. T7 RNA Polymerase (SKU K1083, APExBIO) is a DNA-dependent RNA polymerase expressed in E. coli, optimized for high-yield in vitro transcription from linearized plasmid or oligo templates. This enzyme supports workflows in RNA synthesis for genome editing, RNA vaccine production, and antisense RNA and RNAi research, as described in both the reference study and internal best-practice articles. For streamlined experimental setup and reliable results, researchers may consider integrating this enzyme into their IVT protocols.